Status:
UNKNOWN
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Emesis
Eligibility:
FEMALE
19+ years
Phase:
PHASE4
Brief Summary
For breast cancer patients receiving chemotherapy regimens, the use of a validated emesis (nausea and vomiting) risk calculator will provide superior anti-emetic (nausea and vomiting) control compared...
Eligibility Criteria
Inclusion
- Newly diagnosed invasive breast cancer (stage I-III)
- Scheduled to receive neoadjuvant or adjuvant intravenous anthracycline with cyclophosphamide-based chemotherapy;
- Able to consent and fill study forms
Exclusion
- Received previous chemotherapy
- Symptoms of nausea or vomiting at baseline (disease related)
- On chronic anti-emetic therapy
- On daily corticosteroids prior to initiation of chemotherapy
- Allergic to steroids, 5HT3 or NK-1
- Uncontrolled diabetes
- Medical or psychiatric illness that would interfere with patients' ability to complete the diary
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
323 Patients enrolled
Trial Details
Trial ID
NCT01913990
Start Date
September 1 2011
End Date
December 1 2017
Last Update
January 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6